NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 886.6 DKK | +0.46% |
|
-1.23% | +27.02% |
| 02:33pm | Mickey Mouse on Wall Street |  |
| 07:31am | Fresenius Medical beats earnings expectations, keeps outlook; shares sink | RE |
Presenter SpeechKeyur Parekh (Analysts)Good afternoon all, and thank you for joining us. My na...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
882.6
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.02% | 569B | |
| +33.43% | 700B | |
| -5.12% | 358B | |
| +19.59% | 330B | |
| +4.89% | 287B | |
| +15.62% | 236B | |
| +6.56% | 202B | |
| -9.28% | 197B | |
| +4.26% | 161B | |
| -3.54% | 157B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Transcript : Novo Nordisk A/S, Q3 2022 Earnings Call, Nov 03, 2022